Prognostic role of bcl-xL and p53 in childhood acute lymphoblastic leukemia (ALL)

Cancer Biology and Therapy

Volumn 4, Issue 1, 2005, Pages 39-45

  Addeo, Raffaele ^a   Caraglia, Michele ^b,c   Baldi, Alfonso ^b   D'Angelo, Velia ^a   Casale, Fiorina ^a   Crisci, Stefania ^a   Abbruzzese, Alberto ^a   Vincenzi, Bruno ^d   Campioni, Mara ^b   De Tullio, Maria Teresa ^a   Indolfi, Paolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

ALL; Bax; Bcl xL; Childhood; Event free survival; p53; Prognosis

Indexed keywords

PREDNISONE; PROTEIN BAX; PROTEIN BCL XL; PROTEIN P53; BCL2L1 PROTEIN, HUMAN; PROTEIN BCL 2; PROTEIN BCL X;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INFANT; LEUKOCYTE COUNT; MALE; MUTATIONAL ANALYSIS; PHENOTYPE; PROGNOSIS; REGRESSION ANALYSIS; SEX DIFFERENCE; STATISTICAL ANALYSIS; TREATMENT OUTCOME; ACUTE LYMPHOCYTIC LEUKEMIA; APOPTOSIS; BIOSYNTHESIS; GENE; GENE EXPRESSION PROFILING; GENETICS; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; SURVIVAL;

ADOLESCENT; APOPTOSIS; BCL-X PROTEIN; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION PROFILING; GENES; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 24644522895     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.1.1371     Document Type: Article

References (38)

1. Kerr JFR, Winterford CM, Harmon PD. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 3:2013-26.
2. Hannun YA. Apoptosis and dilemma of cancer chemoterapy. Blood 1997; 89:1845-53.
3. Adam JM, Huang DC, Puthalakath H, Bouillet P, Vairo G, Moriishi K, Hausmann G, O'Reilly L, Newton K, Ogilvy S, Bath ML, Print CG, Harris AW, Strasser A, Cory S. Control of apoptosis in hematopoietic cells by the Bcl-2 family of proteins. Cold Spring Harb Symp Quant Biol 1999; 64:351-8.
4. Tsujimoto Y, Croce CM. Analysis of the structure, transcript, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986; 83:5214-8.
5. Campana D, Coustan-Smith E, Manabe A, Buschle M, Raimondi SC, Behm FG, Ashmun R, Arico M, Biondi A, Pui CH. Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein. Blood 1993; 81:1025.
6. Summers KE, Goff LK, Wilson AG, Gupta RK, Lister TA, Fitzgibbon J. Frequency of the Bcl-2/IgH rearrangement in normal individuals: Implications for the monitoring of disease, in patients with follicular lymphoma. J Clin Oncol 2001; 19:420-4.
7. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerize in vivo with a conserved homolog, bax that accelerates programmed, cell death. Cell 1993; 74:609-19.
8. Reed JC. Bcl-2 and apoptosis regulation. Semin Hematol 1997; 34:9-19.
9. Reed JC. Apoptosis and chemoresistance. In: Ching-Hon Pui, ed. Childhood Leukemias. 1999; 255-65.
10. Chin L, Pomerantz J, DePinho RA. The INK4a/ARF tumor suppressor: One-gene-two products-two pathways. Trends Biochem Sci 1998; 23:291-6.
11. Lane DP. p53, guardian of the genome. Nature 1992; 358:15-6.
12. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Hirai H, Ishikawa F, Takaku F. Mutations of the p53 gene in lymphoid leukemia. Blood 1991; 77:1153-6.
13. Sugimoto K, Hirano N, Toyoshima H, Chiba S, Mano H, Takaku F, Yazaki Y, Hirai H. Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 1993; 81:3022-6.
14. Felix CA, D'Amico D, Mitsudomi T, Nau MM, Li FP, Fraumeni JF Jr, Cole DE, McCalla J, Reaman GH, Whang-Peng J, Knutsen T, Minna JD, Poplack DG. Hereditary and acquired p53 gene mutations in childhood ALL. J Clin Invest 1992; 89:640-7.
15. Wada M, Bartram CR, Nakamura H, Hachiya M, Chen DL, Borenstein J, Miller CW, Ludwig L, Hansen-Hagge TE, Ludwig WD, Reiter A, Mizoguchi H, Koeffler HP. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 1993; 82:3163-9.
16. Blau O, Avigad S, Stark B, Kodman Y, Luria D, Cohen IJ, Zaizov R. Exon 5 mutations in the p53 gene in relapsed childhood ALL. Leuk Res 1997; 21:721-9.
17. awamura M, Ohnishi H, Guo SX, Sheng XM, Minegishi M, Hanada R, Horibe K, Hongo T, Kaneko Y, Bessho F, Yanagisawa M, Sekiya T, Hayashi Y. Alterations of the p53, p21, p16, p15 and RAS genes in childhood T cell all. Leuk Res 1999; 23:115-26.
18. Lam V, McPherson JP, Salmena L, Lees J, Chu W, Sexsmith E, Hedley DW, Freedman MH, Reed JC, Malkin D, Goldenberg GJ. p53 gene status and chemosensitivity of childhood acute lymphoblastic leukaemia cells to adriamycin. Leuk Res 1999; 23:871-80.
19. Meltzer PS. MDM2 and p53: A question of balance. J Natl Cancer Inst 1994; 84:1265-6.
20. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299-303.
21. Marks DI, Kurz BW, Link MP, Ng E, Shuster JJ, Lauer SJ, Carroll D, Brodsky I, Haines DS. Altered expression of p53 and mdm2 proteins at diagnosis is associated with early treatment failure in childhood acute lymhpoblastic leukemia. J Clin Oncol 1997; 15:1158-62.
22. Blagosklonny MW Loss of function and p53 protein stabilization. Oncogene 1997; 16:1889-93.
23. Sturm I. , Kohne CH, Wolff G, Petrowsky H , Hillebrand T, Hauptmann S , Lorenz M, Dorken B , Daniel PT. Analysis of the p53/BAX pathway in colorectal cancer: Low BAX is a negative prognostic factor in patients with the resected liver metastases. J Clin Oncol 1999; 5:1364-74.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
25. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35:1-39.
26. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34:187-220.
27. ang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G, Bhalla K. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human preB leukemia cells. Leukemia 1994; 8:1960-9.
28. Maung ZT, MacLean FR, Reid MM, Pearson ADJ, Proctor SJ, Hamilton PJ, Hall AG. The relationship between bcl-2 expression and response to chemotherapy in acute leukemia. Br J Haematol 1994; 88:105-9.
29. Coustan-Smith E, Kitanaka A, Pui CH, McNinch L, Evans WE, Raimondi SC, Behm FG, Arico M, Campana D. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 1996; 87:1140-6.
30. ala JL, Vermylen C, Cornu G, Ferrant A, Michaux JL, Philippe M, Martiat P. High expression of bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt's subtype at presentation, and is not correlated with the prognosis. Ann Hematol 1994; 69:17-24.
31. Tsurusawa M, Saeki K, Katano N, Fujimoto T. Bcl-2 expression and prognosis in childhood acute leukemia. Children's Cancer and Leukemia Study Group. Pediatr Hematol Oncol 1998; 15:143-55.
32. Uckun FM, Yang Z, Sather H, Steinherz P, Nachman J, Bostrom B, Crotty L, Sarquis M, Ek O, Zeren T, Tubergen D, Reaman G, Gaynon P. Cellular expression of antiapoptotic bcl-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: A children's cancer group study. Blood 1997; 89:3769-77.
33. Baghdassarian N, Bertrand Y, Ffrench P, Duhaut P, Bryon PA, Ffrench M. Role of BCL-2 and cell cycle regulatory proteins for corticosensitivity assessment in childhood acute lymphoblastic leukaemia. Br J Haematol 2000; 109:109-16.
34. Baghdassarian N, Bertrand Y, Gerland LM, Ffrench P, Duhaut P, Bryon PA, Magaud JP, Ffrench M. Bcl-2, cell cycle regulatory proteins and corticosensitivity in childhood acute lymphoblastic leukaemia. Leuk Lymphoma 2001; 42:1067-75.
35. Stammler G, Sauerbrey A, Zintl F, Volm M. Apoptotic index, Fas and bcl-2 in initial and relapsed childhood acute lymphoblastic leukaemia. Apoptosis 1997; 2:377-83.
36. Salomons GS, Smets LA, Verwijs-Janssen M, Hart AA, Haarman EG, Kaspers GJ, Wering EV, Der Does-Van Den Berg AV, Kamps WA. Bcl-2 family members in childhood acute lymphoblastic leukemia: Relationshipsb with features at presentation, in vitro and in vivo drug response and long-term clinical outcome. Leukemia 1999; 13:1574-80.
37. Gustafsson B, Axelsson B, Gustafsson B, Christensson B, Winiarski J. MDM2 and p53 in childhood acute lymphoblastic leukemia: Higher expression in childhood leukemias with poor prognosis compared to long-term survivors. Pediatr Hematol Oncol 2001; 18:497-508.
38. Tsai T, Davalath S, Rankin C, Radich JP, Head D, Appelbaum FR, Boldt DH.. Tumor suppressor gene alteration in adult acute lymphoblastic leukemia (ALL). Analysis of retinoblastoma (Rb) and p53 gene expression in lymphoblasts of patients with de novo, relapsed, or refractory ALL treated in Southwest Oncology Group studies. Leukemia 1996; 10:1901-10.